NCT03735056 (PrEliMS) is a NA clinical trial of MS Nurse Support in Multiple Sclerosis, sponsored by University of Nottingham.

Who is sponsoring NCT03735056?

NCT03735056 is sponsored by University of Nottingham.

What drugs are being tested in NCT03735056?

Interventions in NCT03735056: MS Nurse Support, Peer Support.

What condition does NCT03735056 study?

NCT03735056 studies Multiple Sclerosis.

Is NCT03735056 still recruiting?

NCT03735056 is currently completed. Last updated 9 November 2020.

Last reviewed 2020-11-09 · How we verify

NCT03735056: PrEliMS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The PrEliMS Feasibility Trial

Completed NA Last updated 9 November 2020

What this trial tests

NA trial testing MS Nurse Support in Multiple Sclerosis in 40 participants. Completed in 31 October 2020.

Timeline

30 November 2018

Primary endpoint
31 October 2020

31 October 2020

Quick facts

Lead sponsor	University of Nottingham
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	supportive care
Enrollment	40
Start date	30 November 2018
Primary completion	31 October 2020
Estimated completion	31 October 2020
Sites	1 location across United Kingdom

Drugs / interventions tested

MS Nurse Support
Peer Support

Conditions studied

Multiple Sclerosis — all drugs for Multiple Sclerosis →

Sponsor

University of Nottingham

Who can join

18 and older, any sex, with Multiple Sclerosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The PrEliMS study is a mixed-methods feasibility randomised controlled trial of a point of diagnosis intervention programme which aims to provide emotional support for newly diagnosed people with Multiple Sclerosis (MS). This feasibility study will enable us to plan for a definitive trial to evaluate the clinical and cost-effectiveness of this point of diagnosis intervention programme. The aim is to assess the feasibility of the trial procedures and intervention, and to evaluate the key feasibility parameters before proceeding to a definitive trial. Participants (N=60) will be randomised into three groups: (1) usual care; (2) usual care + Support 1 (MS Nurse Support); (2) usual care + Support 2 (MS Nurse Support plus Peer Support).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Providing Emotional Support During the Process of Multiple Sclerosis Diagnosis (PrEliMS): A Feasibility Randomised Controlled Trial.
das Nair R, Mhizha-Murira JR, Topcu G, Tindall T, et al · · 2024 · PMID 39318328 · DOI 10.1177/02692155241284781

Verify or expand the search:

Other recruiting trials for Multiple Sclerosis

Currently open trials in the same condition.

NCT07507084 — The Effect of Internal- or External-Focused Exercise Training, Administered in Conjunction With a Cognitive Task, on Wal · NA · recruiting
NCT07524231 — Evaluation of the Effects of Laughter Yoga · NA · recruiting
NCT07489794 — URINARY INCONTINENCE AND PELVIC FLOOR MUSCLE ACTIVITY IN MULTIPLE SCLEROSIS · recruiting
NCT07236684 — Identification of Factors Related to UI in Patients With MS and EMG Assessment of PFM Activity · recruiting
NCT07500727 — Skeletal Muscle Aging and Responsiveness in Aged People With MS · NA · recruiting

Other University of Nottingham trials

Trials by the same sponsor.

NCT07518381 — Medication Understanding in MS · not yet recruiting
NCT07355556 — Technology Supported Improvement, Management and Prevention of Accidental Falls in Hospitals · not yet recruiting
NCT07506408 — Randomised Study of Web-Based Auditory Training With Varying Perceptual and Cognitive Demands on Training Gains and Gene · NA · recruiting
NCT07237529 — What is the Feasibility of Narrative Exposure Therapy (NET) for People Experiencing Psychosis? · NA · not yet recruiting
NCT07237997 — Protein Supplementation During Dialysis (PROSED) · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03735056 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Nottingham
Last refreshed: 9 November 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03735056.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing